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ABSTRACT 
 
The effect of COX-2-dependent prostaglandins (PGs) in acute liver injury has been 
investigated in transgenic mice that express human COX-2 in hepatocytes. We have 
used three well established models of liver injury: Lipopolysaccharide injury in 
D-galactosamine preconditioned mice (LPS/D-GalN), the hepatitis induced by 
concanavalin A (ConA) and the proliferation of hepatocytes in regenerating liver after 
partial hepatectomy (PH). Our data demonstrate that PGs synthesis decreases in 
hepatocytes the susceptibility to LPS/D-GalN or ConA-induced liver injury as deduced 
by significant lower levels of the pro-inflammatory profile and plasmatic 
aminotransferases in transgenic mice, an effect suppressed by COX-2 selective 
inhibitors. These transgenic animals express higher levels of anti-apoptotic proteins and 
exhibit activation of proteins implicated in cell survival, such as Akt and AMP-kinase 
after injury. The resistance to LPS/D-GalN induced liver apoptosis involves an 
impairment of procaspase 3 and 8 activation. Protection against ConA-induced injury 
implies a significant reduction in necrosis. Moreover, hepatocyte commitment to start 
replication is anticipated in Tg mice after PH, due to the expression of PCNA, cyclin D1 
and E. These results show, in a genetic model, that tissue-specific COX-2 dependent 
PGs exert an efficient protection against acute liver injury by an 
antiapoptotic/antinecrotic effect and by accelerated early hepatocyte proliferation. 
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INTRODUCTION 
 
The acute or chronic liver injury, caused by viral infection, autoimmune 
reactions, alcohol ingestion, or the use of certain drugs, results in severe pathologies 
including fulminant hepatitis, cirrhosis and hepatocellular carcinoma (HCC). Chronic 
hepatitis is a prolonged inflammatory process, with inflammatory cells infiltrating the liver 
parenchyma and triggering hepatocyte death. Persistent hepatocyte cell death is 
followed by a regenerative response in which viable hepatocytes are stimulated to 
proliferate to restore the loss of hepatic parenchyma [1].  
Cyclooxygenase-1 (COX-1) and –2 catalyze the first step in prostanoid 
biosynthesis [2]. COX-1 is constitutively expressed in many tissues and seems to be 
involved in the housekeeping function of prostaglandins (PGs) [3], whereas COX-2 is 
induced by a variety of stimuli such as growth factors, pro-inflammatory stimuli, 
hormones and other cellular stresses [4]. Adult hepatocytes fail to induce COX-2 
expression regardless of the pro-inflammatory factors used; however, Kupffer, stellate, 
immortalized mouse liver cells and fetal hepatocytes retain the ability to express COX-2 
upon stimulation with LPS and pro-inflammatory cytokines [5, 6]. In addition to this, we 
reported that partial hepatectomy (PH) induced COX-2 in hepatocytes and this 
contributed to the progression of cell cycle after PH [7, 8]. Expression of COX-2 has 
been also detected in human and animal models of cirrhosis [9], after hepatitis B and C 
virus infection [10, 11], in hepatoma cell lines [12] and in well-differentiated HCC [13]. 
Despite these observations, the question of whether COX-2 expression is 
sufficient to induce tumorigenesis and the contribution of COX-2-dependent PGs to the 
inflammatory injury in liver has not been properly addressed [1, 14]. To gain insight into 
the role of PGs in acute and chronic liver diseases, we have developed a transgenic 
mouse that expresses human COX-2 constitutively in hepatocytes under the control of 
the human ApoE promoter. These mice exhibited a normal phenotype but they were 
resistant to Fas-mediated apoptosis [15]. Although it is widely accepted that PGs 
contribute to the pathology of various inflammatory diseases, which provide the rational 
for the development of COX selective inhibitors [16], different reports suggest that PGE2 
plays a protective role in various animal models of liver injury [17]. Based on these data, 
we sought to examine the response of the COX-2-Tg mice in two well established 
models of inflammatory liver injury: LPS-injury in D-GalN preconditioned mice, an 
experimental model for fulminant hepatitis in sepsis, and the hepatitis induced  
 
by intravenous injection of ConA, a model relevant to autoimmune hepatitis. Our data 
clearly show that PGE2 produced by COX-2 in hepatocytes enhances the levels of 
anti-apoptotic proteins, decreases the susceptibility to apoptosis after LPS/D-GalN 
challenge; attenuates the T-cell dependent hepatitis in response to ConA administration, 
and accelerates the expression of proteins that are involved in the proliferation of 
hepatocytes in regenerating liver after PH. 
 
 
 
MATERIAL AND METHODS 
Chemicals 
Antibodies were from Santa Cruz Laboratories (Santa Cruz, CA), Becton & Dickinson 
(New Jersey, NY) and Cell Signaling (Boston, MA). 5, 5-Dimethyl-3(3-fluorophenyl)- 
4-(4-methylsulphonyl) phenyl-2(5H)-furanone (DFU) was from Merck (Rahway, NJ). 
Reagents were from Roche Diagnostics (Mannheim, Germany) or Sigma Chemical Co. 
(St. Louis, MO). LPS (from Salmonella Thyphimurium), D-GalN and ConA were 
obtained from Sigma. Fluorescent probes were from Molecular Probes (Eugene, OR, 
USA) and Calbiochem (Merck KGaA, Darmstadt, Germany). Akt inhibitor II was from 
Merck (UK). Reagents for electrophoresis were obtained from Bio-Rad (Hercules, CA). 
Liver injury and regeneration models 
To generate mice expressing a human COX-2-Tg in the liver, we used a pLiv-Le6 
vector that contains the constitutive human ApoE gene promoter and its hepatic control 
region [15]. 12 weeks-old Tg animals (C57BL/6JxDBA) and its corresponding wild 
type (Wt) littermates were injected intraperitoneally (i.p.) with 1g/kg D-GalN plus 35 
μg/kg LPS. ConA was intravenous (i.v.) injected through the tail vein at a dose of 20 
mg/kg. Untreated animals received 0.5 ml of NaCl 0.9%. For PH, mice were 
anesthetized with a 92:7 mg/kg mix of ketamine/xylacine and subjected to midventral 
laparotomy with 70% liver resection (left lower and upper and right upper lobes) as 
described [7]. In some experiments, mice were treated daily for four days with DFU (1 
mg/kg) to inhibit COX-2 [18]. Plasma was obtained by puncture of the retro-orbital vein 
plexus. Animals were sacrificed at six or eight h after LPS/D-GalN or ConA treatment, 
respectively. Livers were rapidly removed and freeze-clamped in liquid N2 or collected 
in a solution containing 30% sucrose in PBS. Animals were treated according to the 
Institutional Care Instructions. 
Cytokine analysis 
The plasma levels of IFN-, TNF-, IL-1 and IL-6 were measured by fluorimetry using 
Bio-Plex Suspension Array System (Cytokine Assay) according to the manufacturer’s 
instructions (Bio-Rad). 
Determination of metabolites 
PGE2 was determined in liver tissue by specific immunoassay (Amersham). Briefly, 
liver samples were homogenized in 0.1 M phosphate buffer pH 7.5, containing 0.9% 
BSA and 0.5% Kathon (assay buffer). After centrifugation, the PGs were analyzed 
according to manufacturer’s instructions. Amino transferases, ALT and ASP, alkaline 
phosphatase, ALP, and lactate dehydrogenase, LDH, were assayed 
spectrophotometrically in plasma in the School of Clinic Biochemistry, Faculty of 
Pharmacy, Complutense University, Madrid, Spain. Protein levels were determined with 
the Bradford reagent (Bio-Rad). 
Histochemistry and immunofluorescence 
Samples of liver were fixed in 10% buffered formalin, embedded in paraffin wax, 
sectioned at 3 μm and stained with hematoxylin and eosin (H&E). Histopathology 
analysis was carried out by the Department of Medicine and Animal Surgery from 
Faculty of Veterinary, Madrid, Spain. For immunofluorescence analysis, liver samples 
from 30% sucrose solution in PBS, were snap-frozen in 2-methylbutane immersed in 
liquid N2, and serial 8 m-thick sections were cut onto gelatinized glass with a Microm 
HM550 sledge cryostat [15]. The preparations were fixed with 4% paraformaldehyde 
pH 7 for 30 min at room temperature (RT), washed with PBS and permeabilized with 
methanol for 15 min at RT. For the detection and quantification of apoptosis, the 
TUNEL commercial kit for cell death detection (Roche) was used following the 
instructions of the manufacturer. TO-PRO-3 (Molecular Probes) was used for DNA 
staining. 
Western blot analysis 
Tissue samples (100 mg) were homogenized in a lysis buffer as described [15]. For 
Western blot analysis, extracts were boiled for 5 min in Laemmli sample buffer, and 
equal amounts of protein (50-70 g) were separated by 10-15% SDS-PAGE. The 
relative amounts of each protein were determined in total extracts with the following 
polyclonal or monoclonal antibodies: COX-2, COX-1 and PGES (cytosolic and 
membrane) (Cayman and Santa Cruz), inhibitors of apoptosis (xIAP) (B & D Systems), 
Bcl-2 family proteins (Santa Cruz and Abcam), TNFR pathway (Santa Cruz and Cell 
Signaling), cell cycle proteins, cyclin E, D1, PCNA (Santa Cruz), Akt, and p-Akt (Ser 
473), AMPK and p-AMPK (Thr172) (Cell Signaling). After incubation with the 
corresponding anti-rabbit or anti-mouse horseradish peroxidase conjugated secondary 
antibody, blots were developed by the ECL protocol (Amersham). Target protein band 
densities were normalized with p85. The blots were revealed, and different exposition 
times were performed for each blot with a charged coupling device camera in a 
luminescent image analyzer (Gel-Doc, Bio-Rad). 
Caspase assays. 
Livers were homogenized in 20 mM HEPES pH 7.5; 2 mM DTT and 10 % glycerol. 
The extracts were centrifuged at 8000g for 15 min at 4ºC and 0.5 mg/ml of protein 
supernatant was used to measure caspase activities by cleavage of specific fluorogenic 
substrates in accordance with the supplier’s instructions (BD PharMingen). Substrates 
were N-acetyl-DEVD-7-amino-4-trifluoromethylcoumarin for caspase 3 and N-acetyl- 
IETD-7-amino-4-trifluoromethylcoumarin for caspase 8. The linearity of caspase assays 
was determined over a 30 min reaction period. 
Data analysis 
Data are expressed as means ± standard deviation (SD). Statistical significance 
ofdifferences between the control and transgenic groups was evaluated by the U of 
Mann-Whitney test. All tests have been calculated two-tail, and the significance has 
been considered at P< 0.05. 
 
RESULTS 
Expression of h-COX-2 and PGE2 levels in Tg mice after LPS/D-GalN treatment. 
To achieve selective expression of COX-2 in hepatocytes, we generated 
transgenic (Tg) mice carrying the human isoform of COX-2 (h-COX-2) under the 
control of the human ApoE promoter and its endogenous hepatic control region [15]. 
The levels of h-COX-2, COX-1 and microsomal PGE synthase, which catalyzes the 
isomerization of PGH2 to PGE2, were analyzed in liver extracts from Wt and Tg mice 
after LPS/D-GalN administration. As shown in Fig. 1A, h-COX-2 was significantly 
expressed in Tg animals but was not detectable in the Wt. Total COX-2 (human and 
endogenous) was also increased in Tg mice. Low levels of mPGES-1, which preferently 
couples with COX-2 activity to increase the production of PGE2, and COX-1 were 
present in Wt and Tg mice and did not change after treatment with LPS/D-GalN. The 
protein levels of cPGES were higher than those of mPGES-1 and did not change after 
the injury (Fig. 1A); mPGES-2 levels were negligible (not shown). Treatment of the 
animals with the COX-2 selective inhibitor DFU reduced ( 75%) the PGE2 synthesis 
(Fig. 1B). 
 
 
Inhibition of pro-inflammatory cytokines and liver injury in COX-2-Tg mice after 
LPS/D-GalN treatment. 
LPS/D-GalN administration represents an experimental model of fulminant 
hepatitis in sepsis. LPS is one of the most potent TNF- inducers, but normally LPS or 
TNF- do not cause liver apoptosis unless coadministered with D-GalN which blocks 
transcription in the liver. To analyze the effect of PG synthesis on LPS/D-
GalNdependent 
injury, the levels of the pro-inflammatory cytokines TNF-, IL-1 and IL-6 
were determined. As Fig. 2A shows, a significant increase of circulating cytokine levels 
was observed in Wt mice by the effect of the injury, but this was much lower, about 
50%, in COX-2-Tg mice. When COX-2-Tg mice were treated with DFU, cytokine 
levels resembled those of the Wt animals. The activities of hepatic injury markers AST, 
ALT, ALP and LDH were analyzed after 6 h of LPS/D-GalN administration. After 
hepatic injury, the increase in plasma levels of aminotransferases observed in 
COX-2-Tg mice was much lower than in the Wt ( 80%). When COX-2 was inhibited 
by treatment with DFU, the protection in the Tg animals was lost (Table I). A 
representative histological analysis of liver sections of Wt and Tg mice treated with 
LPS/D-GalN is shown in Fig. 2B. After 6 h following LPS/D-GalN administration, the 
liver from Wt mice exhibited an important focal necrosis of hepatocytes. In contrast, no 
evident lesions were observed in the livers of Tg mice. When Tg animals were treated 
with DFU, necrosis and a focal mild hepatitis were observed resembling the Wt liver. 
To determine the contribution of apoptosis to liver injury, TUNEL of histological liver 
sections and measurement of the caspase 3 and 8 activities were carried out. As shown 
in Fig. 2C, a significant decrease in TUNEL staining was observed in Tg animals 
compared with Wt. Moreover, when Tg animals were treated with DFU, again TUNEL 
increased after LPS/D-GalN administration. The activity and protein levels of the active 
form of caspase 3 were markedly lower in Tg liver after LPS/D-GalN treatment than in 
Wt counterparts (40% and 30% for caspase 3 and 8, respectively; Fig. 4A-B). 
 
COX-2 dependent PGs prevent liver injury induced by ConA. 
ConA induced liver injury is mediated by the activation of the innate and 
adaptive immune cells including natural killer cells (NK), Kupffer cells and CD4+ T 
cells and their production of inflammatory cytokines, such as IL-6, IL-2, TNF- and 
IFN- [19]. Tg animals expressing COX-2 in liver exhibited a significant decrease of 
ConA-induced injury, mainly in IFN-, IL-1 and IL-6 levels (Fig. 3A), as well as on 
liver injury markers (Table II). Histological analysis of liver sections of Wt and Tg mice 
treated with ConA is shown in Fig. 3B. Livers from Wt mice exhibited focal mild areas 
of necrosis in hepatocytes whereas no remarkable lesions were observed in Tg mice. 
Caspase 3-like activity was minimally induced in both Wt and Tg mice by the effect of 
ConA (note the difference of magnitude vs. the LPS/D-GalN model), and a minimal 
processing of procaspase 3 was observed in the Wt mice (Fig. 4C-D). 
Altered expression of apoptotic related proteins after liver injury in h-COX-2 Tg 
mice. 
To address the anti-apoptotic mechanism of COX-2 acting upon LPS/D-GalN or 
ConA mediated liver injury, we investigated the expression of apoptosis-related 
proteins. As Fig. 5A shows, the protein levels of TNFR1, TRADD and xIAP were 
equivalent in Wt and Tg mice and no differences were found after treatments. Bax was 
increased in Wt mice after injury and no changes were observed in Tg mice. Bcl-2 and 
Mcl-1 levels were increased in Tg liver under basal conditions and were maintained 
after LPS/D-GalN treatment. TNFR2 and TRAF2 (TNF receptor-associated factor 2) 
decreased by the effect of the treatment in Wt but not in COX-2 expressing liver, 
indicating an increased sensitivity to TNF-induced apoptosis in Wt mice. Moreover, an 
increase in the Bcl-2/Bax (170%) ratio was observed in Tg mice after LPS/D-GalN 
treatment (Fig. 5C). Similar results were obtained when all these parameters were 
measured in Wt and Tg mice treated with ConA (Fig. 5B-D). 
The PI3K/Akt and AMPK pathways play a central role in integrating diverse 
survival signals. An increase in the p-Akt/Akt (>3 fold) and more moderate in the 
p-AMPK/AMPK (1.5 fold) ratio were observed in Tg mice after LPS/D-GalN (Fig. 
6A) or ConA injury (Fig. 6B). To confirm the contribution of PGs synthesis on Akt 
phosphorylation, we performed experiments in liver cell lines with stable expression of 
COX-2 as described previously [20]. A significant inhibition of the apoptosis induced 
by the effect of LPS/D-GalN in CHL-C cells (cells transfected with COX-2) comparing 
with the CHL-V cells (cells transfected with empty vector) was observed. Moreover 
when cells were treated with the specific Akt inhibitor II, the number of apoptotic 
CHL-C cells was doubled indicating that Akt activation plays an important role in the 
inhibition of apoptosis promoted by PGs (Fig. 6C). To know the contribution of PGs to 
AMPK activation, CHL-C and CHL-V cells were treated with LPS/D-GalN and, as 
shown in Fig. 6D, AMPK was phosphorylated under basal conditions in agreement with 
the in vivo results (Fig. 6A). When CHL-V cells were treated with LPS/D-GalN, AMPK 
activation decreased; however, CHL-C or CHL-V cells treated with PGE2, maintained 
the phosphorylation state of AMPK. DFU treatment reversed theses effects. 
To gain further insight into this differential response to liver injury in Wt and 
COX-2-Tg mice, we used a specific mouse apoptosis micro array to compare the 
expression profile after treatment with LPS/D-GalN. Fig. 7A summarizes both the 
magnitude of changes and the corresponding statistical significance of the 84 
apoptosisrelated genes analyzed. We sorted the candidate genes whose expression 
threshold after LPS/D-GalN treatment was altered more than 2-fold (Fig. 7B). As we 
expected from the previous results, the majority of the up-regulated genes in Wt treated 
mice were proapoptotic (Apaf1, Casp1, Casp14, Casp4, Fasl, Tnf, Tnfsf10, Trp63, 
Trp73) and the down-regulated genes were anti-apoptotic (Api5, Bag3, Birc5, Dapk1, 
Mcl1, Sphk2, Traf2, Zc3Hc1). However, Tg mice exhibited opposite and attenuated 
changes of these genes (Api, Bag1, Bax, Plob, Traf2). 
 
 
 
COX-2 Tg mice exhibit an accelerated hepatocyte proliferation after PH. 
Because liver regeneration after PH implies a negligible apoptosis under normal 
conditions, we decided to evaluate the effect of the COX-2 Tg after PH. As previously 
described [7], COX-2 protein levels increased after PH and the levels of COX-1 and 
mPGES did not change (Fig. 8C). Fig. 8A shows similar survival rates for Wt and Tg 
mice after PH and no significant differences were found in the liver regeneration index 
at 80 h after PH (Fig. 8B). When cell cycle proteins were analyzed, significant 
differences were found in the levels of proliferating cell nuclear antigen (PCNA), cyclin 
D1 and cyclin E between Tg and the corresponding Wt mice. As shown in Fig. 8D-E, 
cyclin D1 was present in Tg mice at 0 h, increased at 12 h and remained elevated at 24 
h after PH; cyclin E increased at 12 h and the raise of PCNA after PH was evidenced at 
48 and 96 h. 
DISCUSSION 
We have studied the effect of constitutive expression of COX-2 in the 
hepatocyte on the liver response to three distinct insults: LPS/D-GalN, ConA and PH. 
These Tg animals exhibited higher levels of some anti-apoptotic genes of the Bcl-2 
family and were significantly resistant to LPS/D-GalN-induced injury, mainly through 
an inhibition of the apoptotic response characteristic of this model. It has been reported 
that D-GalN co-administered with LPS, represents an experimental model for fulminant 
hepatitis in sepsis due to massive hepatocyte apoptosis, mainly caused by an abrupt 
TNF- rise in the absence of transcription [21]. Under these conditions, COX-2 Tg 
animals exhibited a much lesser pro-inflammatory profile than the corresponding Wt 
animals. TNF- signals through two distinct membrane receptors: TNFR1 and TNFR2. 
TNFR1, but not TNFR2 can directly activate the caspase 8 apoptotic pathway through 
its cytoplasmic death domain (DD) [22]. Through TRADD, TNFR1 engagement also 
leads to IKK and JNK activation. While IKK activation has a clear antiapoptotic 
function, different results have been reported for the role of JNK activation in 
TNF--induced apoptosis [23]. Our data show a decrease in TNFR2 by the effect of 
LPS/D-GalN treatment in Wt mice and this may be due to a down-regulation of the 
receptor described during endotoxemia [24]. Although TNFR2 lacks a death domain, it 
has also been associated with the apoptotic response to TNF-. It is known that TNFR2 
triggering induces degradation and depletion of TRAF2 and IAP proteins and 
accelerates TNFR1-dependent activation of caspase 8 [25]. TRAF2 protein levels were 
depleted by the effect of the injury in Wt mice but not in the COX-2-Tg liver supporting 
the hypothesis that TRAF2 provides anti-apoptotic signals following TNF-stimulation. 
Intravenous administration of ConA is an excellent model resembling 
immunemediated fulminant hepatic failure in humans. As reported [26], ConA rapidly 
induced (6-24 h) clinical and histological evidenced of hepatitis, including elevation of 
transaminases, T cell infiltration and necrosis. ConA-induced liver injury is mediated by 
the activation of the innate and adaptive immune cells including NKs, Kupffer cells and 
CD4+ T cells and their production of inflammatory cytokines, such as TNF- and 
IFN-. IFN- plays a critical role in T cell-dependent liver injury initiated by ConA 
since IFN- KO mice are protected from hepatic injury [27]. In agreement with this 
mechanism, treatment with ConA produced a rise in IFN- levels, an effect that was 
markedly reduced in COX-2 Tg mice, which suggests that PGs are interfering on 
immune cell activation, in particular lymphocytes. In this regard, it should be mentioned 
that previous work described an inhibitory effect by PGs on T cell activation [28]. The 
activation of caspase 3 observed in ConA-treated mice was less than 80% of that 
observed after LPS/D-GalN challenge and, indeed, a negligible procaspase 3  
processing to caspase 3 was observed in ConA treated animals in our conditions, 
suggesting that ConA is mainly promoting a cytolytic/necrotic response in agreement 
with the rapid rise in plasma levels of transaminases. Although in both liver injury 
models the expression of the COX-2 Tg exerted a very important protection, it is 
noteworthy mention that the cellular and molecular mechanisms underlying this effect 
appear to be different: protection against apoptosis in the LPS/D-GalN model, and 
attenuation of the immunecell dependent hepatocyte necrosis in the case of ConA 
administration. 
The pro-inflammatory and cytoprotective functions of COX-2 in liver remain 
unclear, mainly because hepatocytes, but not other hepatic cells, fail to express COX-2 
upon pro-inflammatory challenge [29]. It has been reported that expression of a COX-2 
Tg causes hepatitis in senescent animals [30]; however, different reports demonstrated 
that PGE2 administration protects against liver injury after E. coli infection by 
suppressing circulating TNF- and IL-12 levels and increasing IL-10 production [31]. 
The PGE2-EP4 signalling pathway effectively protects against hepatic  
ischemia/reperfusion injury because EP4 agonists downregulated the expression of 
several pro-inflammatory cytokines, chemokines and adhesion molecules [17]. PGE2 
downregulates Kupffer cell production of IL-1 and IL-6 during hepatic regeneration and 
LPS liver injury [32] and attenuates the acute phase response through a decrease in 
IL-6-induced -2 macroglobulin formation via a cAMP-dependent signalling [33]. Our 
results agree with these data and show that COX-2-dependent PGs cause an important 
decrease in the plasma levels of pro-inflammatory cytokines and a significant 
improvement in liver function after LPS/D-GalN or ConA challenge compared with the 
Wt counterparts. In this regard, Yin et al. [34] by using COX-2-/- mice demonstrated an 
increased susceptibility of COX-2-/- mice to ConA-induced hepatitis. 
Studies with different Tg mouse models of COX-2 also demonstrated the 
important anti-apoptotic role for PGs. Tg mice expressing COX-2 in mammary gland 
developed tumours, and these animals had reduced levels of the proapoptotic proteins 
Bax and Bcl-xS and elevated levels of the antiapoptotic protein Bcl-2 [35]. A different 
study demonstrated hyperplasic gastric tumours in Tg mice expressing COX-2 and  
PGES. This study relates PGE2 with the recruitment, infiltration and activation of 
mucosal macrophages establishing a relationship between inflammation and tumour cell 
growth [36]. Our previous results obtained with stable expression of COX-2 in liver cell 
lines and with mouse hydrodynamically transfected with a COX-2-GFP expression 
vector, supported the view that PGs produced by COX-2 protected the liver against 
Fas-mediated apoptosis [20]. In this work we show that PGs produced by COX-2 in 
liver, increased the levels of Bcl-2, Mcl-1, TNFR2 and TRAF2, all these hallmarks of 
apoptotic/anti-apoptotic pathway, and were confirmed by a PCR array analysis specific 
for apoptosis profile. Several signalling pathways have been proposed as mediators of 
COX-2-dependent inhibition of apoptosis; however, few reports describe the direct 
effect of COX-2 expression on apoptosis in liver or HCC cells. Leng et al.[37] reported 
an enhanced phosphorylation of Akt in Hep3B cells transiently or permanently 
transfected with a COX-2 expression vector; overexpression of COX-2 in rat intestinal 
epithelial cells increased their resistance to undergo apoptosis and resulted in increased 
Bcl-2 protein levels [38] and COX-2 induces a Mcl-1-dependent survival mechanism in 
human lung adenocarcinoma cells [39]. Targets of PGs through their EP receptors are 
the PI3K and the Akt/PKB pathways. The PI3K/Akt is important in modulating the 
mammalian target of rapamycin, which acts as a central sensor for nutrient/energy 
availability, thereby regulating cell growth. Activation of Akt and G subunit of EP 
receptors can also result in the accumulation of -catenin of the canonical Wnt pathway 
in the nucleus, which also leads to transcriptional activation [40]. Akt improves cellular 
energy stores by accelerating cell proliferation and size, while induces antiapoptotic 
effects by phosphorylation and inactivation of the proapoptotic protein Bad, and by the 
upregulation of Bcl-2 and Mcl-1[41]. Our results show that in the liver of COX-2-Tg 
mice, both Akt and AMP-kinase are phosphorylated indicating a reinforcement of 
survival pathways and a higher efficiency in energetic metabolism, preventing ATP 
depletion [42]. These circumstances concur in favouring liver protection after acute 
injury. 
It has been described [7, 43] that PGs produced by COX-2 are important for the 
early steps of liver regeneration after PH. Because liver regeneration after PH is 
characterized by a negligible concurrence of apoptosis, we investigated whether the 
COX-2 Tg might influence the hepatocyte proliferation. Our results show that PGs 
anticipated the initial cell cycle progression without noticeable changes in the rate of 
mass recovery at the end (5-days) of the regeneration process. As potential 
mechanisms responsible for this rapid cell commitment for proliferation, it is known that 
PGs increase cyclin D1 levels through -catenin pathway [44], and that both AMPK and 
Akt  facilitate cell entry into the cell cycle [45], and these enzymes are ‘more active’ in 
the COX-2-Tg mice. It is relevant to note that continuous generation of PGE2 in the 
hepatocytes contributes to higher levels of cyclins and a more intense expression of 
PCNA. However, these circumstances did not contribute to acceleration in the 
regeneration process, suggesting that rate-limiting factors play a role after PH and 
provide a fine kinetic control for hepatocyte proliferation. 
Finally, although these studies have been performed using acute liver injury 
approaches and showed tissue protection, further studies with this COX-2-Tg mice, 
might help to elucidate whether this COX-2 expression protects or might sensitize 
mouse liver for chronic diseases and carcinogenesis. 
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FIGURE LEGENDS 
Figure 1. Expression of human COX-2 in Tg mice after LPS/D-GalN treatment. (A) 
Human and total COX-2, mPGES-1, cPGES and COX-1 protein expression in liver 
homogenates from Wt and COX-2-Tg animals with or without LPS/D-GalN treatment 
(6 hours) detected by Western blot and normalized with p85. Abs were from Cayman 
and Santa Cruz. (B) Intrahepatic PGE2 concentrations were determined by ELISA in 
liver homogenates in the presence or absence of 1 mg/kg of DFU. Data are the means + 
SD of six animals per condition. *P<0.05 vs. the corresponding Wt animals treated 
under identical conditions. #P 0.05 vs. the corresponding Tg animals treated without 
DFU. 
 
Figure 2. Inhibition of pro-inflammatory cytokines and liver injury in COX-2-Tg 
mice after LPS/D-GalN treatment. (A) TNF-, IL-1 and IL-6 were measured after 2 h 
of treatment in plasma by fluorimetric analysis using Bio-Plex Suspension Array 
System (Bio-Rad). (B) Hematoxylin and eosin (H&E) analysis of liver sections of a 12- 
weeks-old Wt and Tg mice after treatment. Figures were taken with a CVD Camera at 
40X. Scale bar, 50μm. (a) Focal necrosis of hepatocytes in LPS/D-GalN treated Wt 
mice. (b) No lesions were observed in the liver of TG mice under the same conditions. 
(c-d) Diffuse moderate acute and focal mild hepatitis is observed in Wt and Tg mice 
treated with DFU respectively. (C) Apoptosis in liver sections taken 6 hours after 
injection with LPS/D-GalN. Confocal images were obtained with a Leica TCS SP2 
Spectral microscope and a 63x/1.40 NA oil objective (Leica Microsystems, Wetzlar 
Germany). A representative result of TUNEL analysis (red fluorescence) and nuclear 
staining with TO-PRO-3 (blue). Scale bar, 40 μm. Original magnification, 63X. The 
percentage of apoptotic cells was quantified and results show the mean ± SD of five 
sections per animal (n=4). Results are mean ± SD of five animals per condition. *, ** 
denotes P<0.05 and P<0.001 vs. the corresponding Wt mice treated under identical 
conditions. #P 0.05 vs. the corresponding Tg animals treated without DFU. 
 
Figure 3. COX-2 dependent PGs prevent liver injury induced by ConA. ConA was 
i.v. at 20 mg/kg to Wt and Tg mice. (A) Plasma levels of cytokines after 2 h of ConA 
treatment were measured by fluorimetric analysis using Bio-Plex (Bio-Rad). (B) 
Histological analysis of liver sections of a 12-weeks-old Wt littermate and Tg mice after 
ConA treatment and stained with H&E (40X; scale bar, 50 μm). Mild focal necrosis of 
hepatocytes in ConA-treated Wt liver whereas no remarkable lesions were observed in 
the liver of Tg mice. Results are mean ± SD of five animals per condition. *, ** denotes 
P<0.05 and P<0.001 vs. the corresponding Wt mice treated under identical conditions. 
 
Figure 4. Expression of COX-2 inhibits caspase like activities. Caspase 3 and 8 
were measured as DEVDase and IETDase activities in Wt and Tg liver homogenates. 
Caspase activities were measured by fluorimetric assay with specific fluorogenic 
substrates (see Materials and Methods) after LPS/D-Gal N (A-B) or ConA (C-D) 
treatment. Note the different scale in the A-C panel. Liver extracts were also used to 
determine the amount of pro-caspase 3 by Western blot. Blots were normalized for 
protein content with p85. Data are the means + SD of five animals per condition. *P 
0.05 vs. the Wt mice treated under identical conditions. 
 
Figure 5. Altered expression of apoptotic related proteins in COX-2-expressing 
liver. Representative Western blots showing the expression of Bcl-xL, Bcl-2, Bax, xIAP, 
Mcl-1, TNFR1, TNFR2, TRAF-2 and TRADD in Wt and Tg animals. Densitometric 
analysis of the expression of Bcl-2/Bax ratio after LPS/D-GalN (6 h) (A-C) or ConA (8 
h) (B-D) treatment. The expression of target proteins was normalized to that of p85 and 
the ratios are expressed as percentage of the Wt value without treatment. Data are the 
means + SD of six animals per condition. * denotes P<0.05 vs. the Wt mice treated 
under identical conditions. 
 
Figure 6. Akt and AMPK activation in COX-2-Tg mice and in liver cell lines. 
Representative Western blots showing the expression of p-Akt/Akt and p- 
AMPK/AMPK in Wt and Tg animals. Densitometric analysis of the expression of p- 
Akt/Akt after LPS/D-GalN (6 h) (A) or ConA (8 h) (B) treatment. Ab for Akt, and p- 
Akt (Ser 473), AMPK and p-AMPK (Thr172) were from Cell Signaling. (C) CHL-C 
(stable transfected with pcDNA3hCOX-2) and CHL-V (transfected with pcDNA3) cells 
(50x103) were treated with 5 mM D-GalN plus 100 ng/ml LPS or 5 μM Akt inhibitor II 
for 12 h. After that, cells resuspended in PBS were PI-stained and cell viability was 
determined in a BD FACS Canto I cell cytometry. (D) CHL-C and CHL-V cells (1x106) 
were preincubated with 5 M PGE2 or 5 M DFU for 1 h and then treated with 5 mM 
D-GalN plus 100 ng/ml LPS for 12 h. Protein levels of p-AMPK /AMPK were 
measured by Western blot and the densitometric analysis is shown. The expression of 
target proteins was normalized to that of p85 and the ratios are expressed as 
percentage of the Wt value without treatment. Data are the means + SD of six animals 
per condition or three independent experiments. *, ** denotes P<0.05 and P<0.001 vs. 
the Wt mice or the CHL-V cells treated under identical conditions. 
 
Figure 7. Transcriptional profiling of COX-2 expressing liver after LPS/D-GalN 
treatment. Total RNA was isolated from liver with TRIzol Reagent (Invitrogen, 
Carlsbad, California, USA) and further cleaned up using the Qiagen RNeasy MiniKit 
(Hilden, Germany) with one step of DNase I digestion following the manufacturer’s 
instructions. 2 g of RNA were used for cDNA synthesis with RT2 First Standard kit 
(SuperArray Bioscience, Frederick, MD). The mouse apoptosis PCR array was 
performed according to the manufacturer’s protocol, using the Profiler PCR Array 
System and the SYBR Green/Fluorescein qPCR master mix (SuperArray Bioscience) 
on a MyiQ Real-Time PCR System (Bio-Rad). Gene expression was compared with the 
web-based software package for the PCR Array System 
(http://www.superarray.com/pcr/arrayanalysis.php); this software automatically 
performs all Ct based fold-change calculations from the specific uploaded raw 
threshold cycle data. (A) Volcano plot shows the log2 fold change of apoptosis-related 
genes versus their p-values. Each point represents a plot containing log2 of the fold 
change in gene expression threshold for two conditions (saline vs. LPS/D-GalN) on the 
x axis and the p value on the y axis. Points over the horizontal blue line indicated the p- 
value of <0.01. (B) Colorimetric diagram with a selection of the 84 apoptosis-related 
genes analyzed. Genes whose transcription is up/down (red/green) two fold in gene 
expression threshold after LPS/D-GalN treatment are shown. All data presented are the 
means of four animals per condition. 
 
Figure 8. COX-2 expressing hepatocytes exhibit an accelerated proliferation after 
PH. For PH, Wt and Tg mice were subjected to midventral laparotomy with 70% liver 
resection and total extracts were prepared. (A) Survival rates of Wt and COX-2-Tg mice 
at 120 h after PH. (B) Liver regeneration index at the indicated times after PH. (C) COX-
2, mPGES and COX-1 protein expression in liver homogenates from Wt and COX-2-Tg 
animals after PH detected by Western blot and normalized with p85. (D-E) 
Representative Western blots and densitometric analysis of PCNA, cyclin D1 and E in 
Wt and COX-2 Tg mice after PH. Results are the means + SD of the five animals. *, ** 
denotes P<0.05 and P<0.001 vs. the corresponding Wt condition treated under identical 
conditions, respectively. 
TABLE I. Plasma Levels of Liver Injury Markers. 
 
 
Mice     AST (UI/l)  ALT (UI/l)  ALP (UI/l)  LDH (UI/l) 
 
Wt  Saline   84 ± 16  39 ± 7  355 ± 66  47 ± 9 
LPS/D-GalN  3750 ± 694  537 ± 99  400 ± 74  6381 ± 1180 
LPS/D-GalN + DFU 3697 ± 684  ND   529 ± 98  ND 
 
Tg  Saline   71 ± 12  22 ± 4  279 ± 48  33 ± 6 
LPS/D-GalN  624 ± 108*  66 ± 11*  219 ± 38  734 ± 127* 
LPS/D-GalN + DFU 1531 ± 265#  ND   238 ± 41  ND 
 
 
 
Table I. Plasma levels of liver injury markers after LPS/D-GalN treatment. 
Plasma levels of aminotransferases (AST, ALT), alkaline phosphatase (ALP) and lactate 
dehydrogenase (LDH) were assayed spectrophotometrically after 6 h of treatment from 
the different groups of animals. ND, not determined. Results are mean ± SD of five 
animals per condition. *P<0.05 vs. the corresponding Wt animals treated under identical 
conditions. #P 0.05 vs. the corresponding Tg animals treated without DFU. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE II. Plasma Levels of Liver Injury Markers. 
 
 
Mice    AST (UI/l)  ALT (UI/l)  ALP (UI/l)  LDH(UI/l) 
 
Wt  Saline  84 ± 16  39 ± 7  355 ± 66  47 ± 9 
ConA  1372 ± 254  370 ± 68  276 ± 51  3438 ± 636 
Tg  Saline  71 ± 12  22 ± 4  279 ± 48  33 ± 6 
ConA  879 ± 152*  64 ± 11*  183 ± 32  1344 ± 233 *  
 
 
 
Table II. Plasma levels of liver injury markers after ConA treatment. 
Plasma levels of AST, ALT, ALP and LDH were assayed 
spectrophotometrically after 8 h of treatment from the different groups of 
animals. Results are mean ± SD of five animals per condition. *P<0.05 vs. the 
corresponding Wt animals treated under identical conditions. 
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